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Abstract
Background: Infection with bovine herpesvirus-1 (BHV-1) causes a wide range of disease manifestations, including
respiratory disease and abortion, with world-wide distribution. The primary objective of the present study was to
describe aspects of BHV-1 infection and control on Irish farms, including herd-level seroprevalence (based on
pooled sera) and vaccine usage.
Methods: The characteristics of a diagnostic indirect BHV-1 antibody ELISA test when used on serum pools were
evaluated using laboratory replicates for use in the seroprevalence study. The output from this indirect ELISA was
expressed as a percentage positivity (PP) value. A proposed cut off (PCO) PP was applied in a cross-sectional study
of a stratified random sample of 1,175 Irish dairy and beef cattle herds in 2009, using serum pools, to estimate
herd seroprevalence. The study was observational, based primarily on the analysis of existing samples, and only
aggregated results were reported. For these reasons, ethical approval was not required. Bulk milk samples from a
subset of 111 dairy herds were analysed using the same ELISA. Information regarding vaccine usage was
determined in a telephone survey.
Results: A PCO PP of 7.88% was determined to give 97.1% sensitivity and 100% specificity relative to the use of
the ELISA on individual sera giving maximization of the prevalence independent Youden’s index, on receiver
operating characteristics analysis of replicate results. The herd-level BHV-1 seroprevalence was 74.9% (95% CI -
69.9%-79.8%), with no significant difference between dairy and beef herds. 95.5% agreement in herd classification
was found between bulk milk and serum pools. Only 1.8 percent of farmers used BHV-1 marker vaccine, 80% of
which was live while 75% of vaccinated herds were dairy.
A significant association was found between herd size (quartiles) and seroprevalence (quartiles).
Conclusions: The results from this study indicate BHV-1 infection is endemic, although BHV-1 vaccines are rarely
used, in the cattle population in Ireland.
Background
Infection with bovine herpesvirus-1 (BHV-1) causes a
wide range of disease manifestations including respira-
tory disease, abortion and other less common syn-
dromes [1]. Pathogenicity can vary from mild to severe
and relative importance of each syndrome varies
between countries. It has a world-wide distribution,
though some European countries have a long history of
BHV-1 control [2]. A number of Member States within
the European Union (EU) have either successfully eradi-
cated BHV-1 (Denmark, Finland, Sweden, Austria, the
Italian province of Bolzano-Bozen, Switzerland) or
implemented an EU-approved compulsory programme
(Germany, the Italian province of Trento). Herd-level
antibody prevalence of BHV-1 infection shows a wide
variation between countries. The control and eradication
of BHV-1 infections has been previously reviewed [3].
In Ireland, some information has recently emerged
regarding BHV-1 infection, albeit from a biased subset
of Irish beef herds [4] of which 73.2% were seropositive.
As yet, dairy herd-level prevalence has not been evalu-
ated, and data are not available concerning strategies
used to control infection in Ireland, including vaccina-
tion. An understanding of BHV-1 prevalence and vac-
cine use are necessary for designing and implementing
effective national control measures.
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The primary objective of this study was to describe
aspects of BHV-1 infection and control on Irish farms,
including herd-level seroprevalence (based on pooled
sera) and vaccine usage. Preliminary validation of an
indirect BHV-1 antibody ELISA (SVANOVA; Biotech
AB, Uppsala, Sweden) using pooled sera was conducted




Five hundred negative and 500 positive sera (’the
archived sera’) were selected from routine submissions
to the diagnostic unit of Agri-Food and Biosciences
Institute (AFBI) in Belfast. The archived sera were
assayed using the above mentioned BHV-1 antibody
indirect ELISA. These sera were assigned to either of
two groups - known positives or negatives. EU standard
reference sera (EU-1, EU-2 and EU-3) were used to vali-
date the ELISA for use on single serum samples prior to
use in the study [5,6]. The test was performed according
to the instructions of the manufacturer. Both positive
and negative control sera were included in each assay.
Sensitivity (Se) and specificity (Sp) of the test when used
on individual sera relative to serum neutralisation test
(SNT) are 97.4% and 92.4%, respectively (SVANOVA,
data on file).
The archived sera were used to form a series of ‘vali-
dation pools’, each containing 30 sera (20 μL each
serum, 600 μL for each sample pool). Specifically, each
validation pool included a defined number (’n’) of posi-
tive sera (where n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20,
25 or 30) in combination with 30-n negative samples.
For example, one validation pool had 0 positive and 30
negative samples, another had 1 positive and 29 negative
samples, etc. In total, 90 validation pools were created,
including 20 pools where n = 0, and 5 each for the 14
remaining positive/negative combinations. For each of
these validation pools, the positive and negative samples
were selected using simple random sampling from the
archived sera. The 90 validation pools were analysed
using the above-mentioned BHV-1 antibody ELISA, all
in the diagnostic unit of AFBI. The absorbance or opti-
cal density (OD) of each well at 450 nm was measured
on a microplate plate reader. The corrected OD (COD)
value of each pool and reference serum was obtained by
subtraction of the OD value of each control antigen-
coated well from that of the parallel viral antigen-coated
well [7]. A corresponding percentage positivity (PP)
value was obtained using the formula:
PP value = COD (Sample)/COD (Positive Control).
Randomisation in this study was performed using a
computer-generated random number list (Microsoft
Excel 2003).
Seroprevalence study
Pooled serum As part of the national statutory brucello-
sis eradication scheme, serum samples are collected
annually from all eligible animals (female bovines and
entire bulls aged 12 months or over) in all cattle herds in
Ireland. A sample of these herds was selected for the cur-
rent study. Based on data available through the national
Animal Health Computer System database, stratified ran-
dom sampling (based on two strata: ‘province’ and ‘herd
type’) was used. There are four provinces in Ireland
(Connaught, Leinster, Munster and Ulster). Two herd
types were defined in this study - beef (containing > 66%
beef breed cows) and dairy (containing > 66% dairy breed
cows). The number of animals sampled was proportional
to the number of herds with at least one birth registered
in 2008 within each stratum. In 2008, 87,396 herds had
one or more births registered. Of these, 2,037 were
mixed dairy and beef herds and were excluded. A further
30,894 herds were excluded because they were small
(dairy herds < 20 breeding cattle; beef < 10 breeding cat-
tle). The proportion of the remaining 54,465 herds within
each strata is shown in Table 1. The aim was to select a
total sample size of 2688 to allow for random selection of
sufficient herds stratified on herd type (beef or dairy) and
location (province) (Table 2). This sample size was based
on herd-level Se and Sp (calculated from pooled-test Se
and Sp values determined in the validation study) [8], a
herd-level prevalence based on a previous study of 73%
[4], and a participation rate of 50% for farms enrolled in
the study during a 10 week collection period. Throughout
the study period, animals were mostly kept on managed
grassland. While 2688 were initially contacted, 296 herds
had to be excluded as they had either already completed
their herd test prior to the proposed collection period or
their contact details were inaccurate. Hence, 2392 herds
were recruited of which 1659 were classified beef (con-
taining < 30% dairy breed cows) and 733 were dairy (>
70% dairy breed cows), with approximately 204,000 ani-
mals. These farms represented just over 2% of all beef
and dairy herds in Ireland. This represented exclusion of
less than 1% of dairy cows, but almost 15% of beef cows
[9]. Permission for inclusion in the study was sought
from all selected herd owners.
Sample collection was conducted by recruitment of
382 private veterinary practitioners (PVPs) during a ten-
week period from May to August 2009. The study was
observational, based primarily on the analysis of existing
samples, and only aggregated results were reported. For
these reasons, ethical approval was not required. The
serum were placed in deep well blocks and stored fro-
zen. Samples were later thawed, and a serum pool was
generated for each herd, derived from up to 30 indivi-
dual sera (each 10 μL). In herds containing < 30 eligible
animals, the pool included sera from all animals; in
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herds containing > 30 eligible animals, 30 sera were ran-
domly selected based on a randomisation list generated
in Excel 2003. Sample pooling was carried out in Enfer
Diagnostics, Naas, Co. Kildare, Ireland, an officially
accredited laboratory. Testing of the serum pools was
conducted at AFBI using the same indirect ELISA.
Bulk milk 120 dairy herds were selected using conveni-
ence sampling for bulk milk analysis. These were the first
herds from which serum samples were collected. In total,
bulk milk was collected from approximately 20% of all
dairy herds from which sera samples were obtained.
Using a prepared protocol, each herd-owner collected the
bulk milk sample into a 20 mL universal container from
an agitated bulk tank. Containers contained bronopol
preservative tablets and were posted to AFBI for analysis
using the above-mentioned test, for the purposes of com-
parison with results from the sample serum pools.
Vaccine usage survey
A phone survey was used to clarify BHV-1 vaccine
usage in each of the study herds. Each study herd kee-
per was contacted by phone by the first author, and an
interview was conducted regarding duration and timing
of vaccination and brand of vaccine used. National
usage data were obtained from sales data gathered by an
industry survey organization [10]. GfK Kynetec is an
international market research company that gathers data
on sales of animal health products. Using Microsoft
Excel 2003, the data were summarised according to the
number of vaccine doses sold by time of application
(month), and by location (county; 26 in 4 provinces
within the Republic of Ireland).
Data analysis
Preliminary validation
A validation pool was classified positive if it contained ≥
1 positive archived serum sample. The PP values from
each of the 90 validation pools was recorded in a statis-
tical software package (STATA®, Version 11.0/SE; Stata
Corporation, Texas, USA, 2009) and subjected to Recei-
ver Operator Characteristics (ROC) analysis, to deter-
mine the optimal cut-off PP to maximize Se and Sp of
the test when used on pools. However, only values for
Se and Sp when the test is used on individual serum
samples are available (and not pool Se (PSe) and pool
Sp (PSp)) (Manufacturer data on file). We assume that
PSe = Se and PSp = Sp. [11]. Youden’s index was calcu-
lated using the formula (Se+Sp-1) [12].
Seroprevalence study
Pooled serum The OD result of each sample pool was
recorded. The optimal cut-off PP value, as determined
during preliminary validation, was used to classify each
herd as seropositive or negative. Differences in observed
prevalence by herd type, herd size (quartiles) and pro-
vince were tested using a chi-square test.
Bulk milk Bulk milk samples with PP ≥ 3 were deemed
positive, as per manufacturer recommendations. The
statistical software package: STATA®, Version 11.0/SE
(Stata Corporation, Texas, USA, 2009) was used to cal-
culate Cohen’s kappa coefficient, which is a measure of
agreement between the bulk milk results and the sero-
prevalence results. Herds that had a different result in
the bulk milk and seroprevalence studies were further
investigated by whole herd analysis of individual serum
samples to determine which classification was correct.
Vaccine usage
Vaccine usage by seasonality, herd type and brand were
evaluated. Vaccine usage in study herds was compared
to national usage data.
Results
Preliminary validation
There was good agreement between seropositive pools
and seropositivity (R2 = 0.70; Figure 1), and a significant
association between seropositivity and PP (P < 0.001).
Table 1 Proportion of herds with at least one birth during 2008, excluding mixed and small (dairy < 20 animals, beef
< 10 animals) herds, by province and herd type
Province Animals Herds % of herds
Beef Dairy Total Beef Dairy Total Beef Dairy Total
Connaught 264,141 51,439 315,580 12,316 1032 13,348 22.6 1.9 24.5
Leinster 300,933 254,292 555,225 9825 3908 13,733 18.0 7.2 25.2
Munster 304,081 621,957 926,038 11,077 10,174 21,251 20.3 18.7 39.0
Ulster 106,809 73,675 180,484 4752 1381 6133 8.7 2.5 11.3
Total 975,964 1,001,363 1,977,327 37,970 16,495 54,465 69.7 30.3 100.0
Table 2 Number of beef and dairy herds initially
recruited within each province
Province Herd distribution
Beef Dairy Total
Connaught 608 51 659
Leinster 485 193 678
Munster 547 502 1049
Ulster 234 68 302
Total 1874 814 2688
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Based on a ROC analysis of PP readings (Figure 2), a
cut-off PP of 2.63 resulted in a Se and Sp of 100% and
95%, respectively, relative to the use of the ELISA on
individual sera (Table 3). A proposed cut-off (PCO)
PP of 7.88 gave a relative Se and Sp of 97.1% and
100%, respectively. The PCO value was chosen based
on maximization of the prevalence independent criter-
ion (Youden’s index) in order for the ELISA to be
used on bulk serum pools in an Irish seroprevalence
study.
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Figure 2 Receiver operating characteristics curve using
percentage positivity measurements of serum pools containing
assigned proportions of known positive serum samples.
Table 3 Excerpt of detailed report of sensitivity and
specificity from receiver operator characteristic analysis
of ELISA percentage positivity of serum pools by % of










100.00 0.00 77.78 1
(> =
-0.1460)
100.00 5.00 78.89 1.0526 0
(> =
-0.1016)
100.00 10.00 80.00 1.1111 0
(> =
-0.0889)
100.00 15.00 81.11 1.1765 0
(> =
-0.0190)
100.00 20.00 82.22 1.25 0
(> =
-0.063)
100.00 25.00 83.33 1.3333 0
(> = 0.0) 100.00 30.00 84.44 1.4286 0
(> =
0.0127)
100.00 45.00 87.78 1.8182 0
(> =
0.0190)
100.00 50.00 88.89 2 0
(> =
0.0381)
100.00 55.00 90.00 2.2222 0
(> =
0.0508)
100.00 60.00 91.11 2.5 0
(> =
0.0762)
100.00 65.00 92.22 2.8571 0
(> =
0.0889)
100.00 70.00 93.33 3.3333 0
(> =
0.1714)
100.00 75.00 94.44 4 0
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Seroprevalence study
Pooled serum
Sera from 1,175 herds were collected by 199 PVPs. Parti-
cipation was largely influenced by the decision of the
herd-owner on the most suitable seasonal timing of their
brucellosis herd test, with 1217 herds choosing to delay
until after the collection period, mainly for commercial
reasons. Approximately 61,000 sera (from about 60% of
all bovine animals in these herds) were collected during
the study period. Of the collected herds, 450 contained
30 or less samples. Using the PCO determined in the
validation study, 295 herds were classified as seronega-
tive. The highest PP readings in each quartile were 7.3,
67.2, 95.9 and 159% respectively. The herd-level BHV-1
prevalence was 74.9% (95% CI - 69.9%-79.8%). Herd level
prevalences by province and herd type are summarized
in Table 4. There was a significant difference between
provinces for herd-level BHV-1 seroprevalence (P <
0.001), with highest seroprevalence in Leinster and lowest
in Munster. The seroprevalence for dairy and beef herds
was not significantly different (P = 0.868: 74.6% vs
75.0%). Herd-level BHV-1 seroprevalence was signifi-
cantly associated with herd size (Table 5).
Bulk milk
In total, 111 bulk milk samples were collected. The
highest PP readings in each quartile were 1.2, 37.7,
97.1 and 153% respectively. A comparison of the
results from the pooled serum and bulk milk analyses,
using the two different cut-offs, is presented in Table
6. Subsequently, the more-conservative PP of 7.88 was
used to determine herd-based BHV-1 seroprevalence.
Kappa analysis demonstrates 95.5% agreement between
herd classification of seroprevalence based on pooled
serum (73.8%) and bulk milk (71.2%) analysis (Table 6)
when PCO is applied. Misclassification occurred with 5
herds (4 were pooled serum +ve, bulk milk -ve; 1 the
converse). In further evaluation conducted in 2 herds
based on an analysis of whole herd individual serum,
one had been misclassified as negative using bulk milk
analysis (that is, one positive animal in a herd of forty
one) and the other misclassified as negative using
pooled serum analysis (six positive animals in a herd of
124 animals). While the latter observation is in line
with previous findings [13], it must be clarified that the
bulk serum pool contained only two of the positive
animal samples.
Vaccine usage
Interviews were conducted with 1,113 (94.7% of the)
study herd keepers. Of these, 20 (1.8%) used BHV-1
marker vaccine (80% live and 20% inactivated). 75% of
vaccinated herds were dairy. In total, 50% and 25% of
the vaccinated herds had been vaccinating for < 1 and >
1 but < 2 years, respectively. Approximately 470,000
doses of BHV-1 marker vaccine were used in the Irish
market in 2009 (85% live) [10], with a distinctly seasonal
pattern of usage (60% of usage during the months
August to December) [10]. The seasonality of vaccine
usage is summarized in Figure 3.
Discussion and Conclusions
Apparent herd-level seroprevalence of BHV-1 in Ireland
was 74.9%, which is in agreement with previous findings
for bulls [4]. Assuming a test Se and Sp of 97.4% and
Table 3 Excerpt of detailed report of sensitivity and spe-
cificity from receiver operator characteristic analysis of
ELISA percentage positivity of serum pools by % of sero-
positive samples in pool (Continued)
(> =
0.1840)
100.00 80.00 95.56 5 0
(> =
0.1841)
100.00 85.00 96.67 6.6667 0
(> =
0.2413)
100.00 90.00 97.78 10 0
(> =
0.2628)
100.00 95.00 98.89 20 0
(> =
0.4008)
98.57 95.00 97.78 19.714 0.015
(> =
0.4402)
97.14 95.00 96.67 19.429 0.0301
(> =
0.7884)
97.14 100.00 97.78 0.0286
(> =
0.8344)
95.71 100.00 96.67 0.0429
(> =
1.2746)
94.29 100.00 95.56 0.0571
(> =
1.3009)
92.86 100.00 94.44 0.0714
(> =
2.0959)
91.43 100.00 93.33 0.0857
(> =
2.1419)
90.00 100.00 92.22 0.1
Table 4 Herd level prevalence within each province, by
herd type
Prevalence - Number of seropositive herds
(%)
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92.4%, respectively, the true herd-level prevalence is
77.4% (74.98-79.76 - 95% CI). This obviously compares
unfavourably to levels in EU member states that are offi-
cially free while levels in other member states where
information is available are broadly similar to Ireland
[3]. Though not specifically investigated in this study, it
is likely that such high levels in Ireland result from his-
toric management practices and particularly the disper-
sal of animals throughout the country in the context of
national trading at markets [14]. However, this issue
warrants further investigation. Herd-level BHV-1 sero-
prevalence was significantly associated with herd size
which is in line with previous findings, though this may
be a cluster risk factor [15,16].
It is apparent from study herds that vaccine usage in
breeding animals in Ireland is very low (1.8%). Regard-
ing control measures implemented at herd level, only
vaccination was investigated in this study. Recall bias
could have arisen among farmers surveyed. Vaccine
brand used was determined to minimize recall bias and
confusion with vaccines used to control other diseases.
Furthermore, a major difference exists between vaccine
usage in the national cattle population and study herds.
Approximately 471,000 doses of BHV-1 vaccine were
used in the Irish market in 2009 [10]. It is estimated
that the majority of vaccine is used in growing animals
(< 2 years old) prior to housing/shipment rather than
breeding animals. This would explain the distinctly sea-
sonal usage of BHV-1 marker vaccine in the Irish cattle
population prior to housing or export of animals in the
months September to November. This pattern is not
followed in study herds, as included herds consist of
breeding animals. The low number of study herds vacci-
nating precluded investigating any link between seropre-
valence and vaccine uptake.
True herd-level seroprevalence of BHV-1 can be
determined from the number of seropositive pools [8].
The effects of pooling on Se and Sp of tests have been
evaluated previously [8,17]. When a single pooled sam-
ple is collected per herd, the only question that can be
answered is whether the herd is infected or not. Sam-
pling bias from PVPs refusing to participate was mini-
mised by encouraging participation through clear
communication of objectives to participating PVPs with
a commitment to provide herd-level results. Procedures
were implemented to avoid cross-contamination and to
ensure minimization of the effect of cross-contamina-
tion. Cross-reaction with other agents is possible if a
pool contained a viraemic animal. The prevalence of vir-
aemic animals in this study is unknown. However, it has
been suggested that pooling can reduce the impact of
cross-reaction due to the dilution of cross-reacting
agents with samples from non-infected animals [8]. Few
publications exist on the use of ELISA tests on serum
pools [18,19], though pools of 10 are widely used by the
Agence Française de Sécurité Sanitaire des Aliments in
France to assess herd-level prevalence of disease [20]. It
has been found in a previous study that 16.3% of sero-
positive herds had only one cow seropositive while an
additional 8.6% had only two cows seropositive [21].
This means that there is a significant risk that herd-level
prevalence will be under-estimated, using serum pools
Table 5 Chi-squared testing of herd-level bovine herpesvirus-1 (BHV-1) seroprevalence (into quartiles) by herd size (in
quartiles), in 1052 Irish study herds during 2009
Herd-level BHV-1 seroprevalence Herd size Total
Lowest quartile Second quartile Third quartile Highest quartile
Lowest quartile 98a 58 52 54 262
Second quartile 72 85 64 46 267
Third quartile 67 61 75 60 263
Highest quartile 55 43 64 98 260
Pearson Chi-square (9) = 57.1295, P < 0.001
a. That is, there were 98 herds with herd-level BHV-1 seroprevalence in the lowest quartile and herd size in the lowest quartile
Table 6 Comparison of bulk milk and pooled serum bovine herpesvirus-1 (BHV-1) results from 111 herds in Ireland
during 2009
BHV-1 herd status based on bulk milk analysis (PP ≥ 0.03) BHV-1 herd status based on pooled serum analysis
(PP 2.63) (PP 7.88)
Negative Positive Negative Positive
Negative 26 6 28 4
Positive 1 78 1 78
-value 0.839 0.887
The pooled serum results are separately presented at two different cut-off percentage positivity (PP) values (2.63 and 7.88)
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containing only 10 animals. Therefore, up to 30 animals
in each herd were used in the serum pools in this study.
Furthermore, bulk milk sample analysis agreed signifi-
cantly with findings of the same herd bulk serum test
(Table 6). While desirable, analysis of all samples indivi-
dually would have been prohibitively expensive.
The preliminary validation study was carried out to
provide a PCO for use on serum pools of 30 samples. It
is reasonable to assume that this cut-off is applicable to
other serum pools of equal or lower size and could pro-
vide a useful cost-reducing tool in prevalence studies
using this ELISA. Two such cut-offs were found on
ROC analysis of the results and the higher cut-off
(PCO) was used, to maximize the Youden’s index, as a
conservative approach to determining national herd-
level seroprevalence. Furthermore, PCO gave better
agreement when compared to results obtained in the
bulk milk study ( = 0.887 compared to 0.839).
As herd classification is based on pooled tests in the
seroprevalence study, estimation of herd-level Se and
herd-level Sp is more complex because assumptions
must be made about PSe and PSp. In this study it was
assumed PSe = Se and PSp = Sp. However, it is likely
that the PSe would be lower than Se especially when
within-herd prevalence is low and pool size is large. The
dilution effect on PSe will also be dependent on the
exposed animal’s concentration of antibody. In this
study, one positive serum sample in the pool (equivalent
to 3% within-pool prevalence) was used to determine
cut-off in the ROC analysis. Furthermore, within-herd
prevalence in the seroprevalence study is likely to be
approximately 28% [4] Individual animals remain sero-
positive for a relatively long time after infection with
maintained high levels of antibodies [22]. It is therefore
contended that any effect of pool size on PSe will be
mitigated by a combination of these factors. Conversely,
PSp should exceed Sp because dilution should make it
less likely to have a false-positive pooled test result than
a false-positive individual-test result [8]. Finally, there is
95.5% agreement in herd classification between bulk
milk and serum pools, using a manufacturer-recom-
mended and validated cut-off PP for bulk milk [23].
However, larger-scale work is advised on the use of
serum pools with low seroprevalence to confirm the
cut-off found in this study and to more accurately vali-
date the use of this test on serum pools. Finally, it is
important to emphasise that the validation of the ELISA
test on serum pools was performed against the same
ELISA used on individual samples. While this is not
optimal, as the SNT is the accepted gold standard test
for validation, large quantities of serum with known
SNT readings were not available. Many laboratories no
longer routinely carry out this test as it is time and
labour-intensive and requires specialist skills and equip-
ment for interpretation. However, the ELISA has been
validated by the manufacturers against the SNT when
used on individual sera, with a Se and Sp of 97.4% and
92.4%, respectively.
Significant future challenges exist in Ireland regarding
BHV-1 infection with herd size increasing and no
national control programme in place [4]. Two produc-
tion strata for cow farms are described in Ireland - beef
suckler farms (n = 74,800) containing 1.105 million
cows and dairy farms (n = 26,800) containing 1.087 mil-
lion dairy cows, with average herd size 15 and 41,
respectively [24]. A small proportion of herds are both
dairy and beef suckler [25]. Numbers of farms are falling
by 3-4% per year as average farm size increases. The low
uptake of vaccine in herds of adult cows will do little to
restrict virus circulation among adult or juvenile stock.
Vaccination has been demonstrated to effectively reduce
seroprevalence if vaccine usage is conducted in a
Figure 3 Seasonality of bovine herpesvirus-1 vaccine usage in Ireland during 2009, both nationally and in the study herds.
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coordinated manner [26]. In addition to those EU mem-
ber states already officially free of disease, other countries
have already achieved regional eradication (France, Ger-
many, UK, Spain and Italy) or are at various stages of
herd certification/eradication (Netherlands, Belgium and
Poland among others) [27]. Further efforts are required
by Animal Health Ireland and other agencies in the
Republic of Ireland in order to avoid high herd-level pre-
valence of BHV-1 acting as a potential barrier to within-
community trade [28]. These would include increasing
awareness of this prevalent disease and encouraging
implementation of cost-effective controls, including
screening, vaccination (particularly of breeding animals),
biosecure practices and a herd accreditation programme.
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